Holocene Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Holocene Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-848,177	Closed	-$53.9M	–	1048
2022 Q1	$69.7M	Sell	848,177 -193,240	-19%	-$19.8M	0.36%	87
2021 Q4	$153M	Buy	1,041,417 +248,024	+31%	+$38.5M	0.8%	29
2021 Q3	$140M	Buy	793,393 +70,171	+10%	+$11.3M	0.76%	29
2021 Q2	$117M	Buy	723,222 +414,251	+134%	+$66.5M	0.66%	38
2021 Q1	$52.9M	Sell	308,971 -27,689	-8%	-$5.48M	0.33%	99
2020 Q4	$73.9M	Buy	336,660 +69,978	+26%	+$15.1M	0.47%	63
2020 Q3	$44.3M	Sell	266,682 -61,148	-19%	-$8.37M	0.34%	95
2020 Q2	$37.4M	Sell	327,830 -76,849	-19%	-$7.45M	0.33%	92
2020 Q1	$31.1M	Buy	404,679 +192,748	+91%	+$17.3M	0.33%	92
2019 Q4	$27.3M	Buy	211,931 +105,207	+99%	+$10.1M	0.24%	115
2019 Q3	$8.31M	Buy	+106,724	New	+$10M	0.09%	139

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Holocene Advisors's MRTX Position: Q2 2022 in Review

Holocene Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 848,177 shares — an estimated $53.9M sold.

Holocene Advisors first reported a position in MRTX in Q3 2019 and held it in 11 quarters. The position peaked at $153M in Q4 2021. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

Holocene Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Holocene Advisors sold 848,177 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $53.9M.
Holocene Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
Holocene Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $153M in Q4 2021.
230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Holocene Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.